Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.30 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21245024 | 1.00 | SMYD3 (0.36) | SMYD3CASRSCN10AKIF18AP2RX7 | |
| SCHEMBL21244779 | 1.00 | SMYD3 (0.36) | SMYD3CASRSCN10AKIF18AP2RX7 | |
| SCHEMBL21244681 | 0.97 | SMYD3 (0.36) | SMYD3CASRSCN10AKIF18AP2RX7 | |
| SCHEMBL21274946 | 0.97 | SMYD3 (0.36) | SMYD3CASRSCN10AKIF18AP2RX7 | |
| SCHEMBL21275102 | 0.96 | SMYD3 (0.35) | SMYD3CASRSCN10AKIF18AP2RX7 | |
| SCHEMBL21244622 | 0.96 | SMYD3 (0.35) | SMYD3CASRSCN10AKIF18AP2RX7 | |
| SCHEMBL21275110 | 0.94 | SMYD3 (0.34) | SMYD3CASRSCN10AKIF18ACA1 | |
| SCHEMBL21244591 | 0.94 | SMYD3 (0.34) | SMYD3CASRSCN10AKIF18ACA1 | |
| SCHEMBL21275387 | 0.93 | SMYD3 (0.35) | SMYD3CASRSCN10AKIF18ACCNT1 | |
| SCHEMBL21244609 | 0.93 | SMYD3 (0.35) | SMYD3CASRSCN10AKIF18ACCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013741-B1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMA (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11873300-B2 | Crystalline forms of CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-16 | — | — | US | disclosed |
| US-11866450-B2 | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-12-14 | — | — | US | disclosed |
| EP-4259139-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230303589-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-09-28 | — | — | US | disclosed |
| EP-4218754-A2 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4198037-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2023-06-21 | — | — | EP | disclosed |
| US-11591350-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3880197-B1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2021030556-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030554-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030555-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021030552-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-18 | — | — | US | disclosed |
| US-20210047323-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2021-02-18 | — | — | US | disclosed |
| EP-3752510-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | Vertex Pharmaceuticals Incorporated (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020102346-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2019161078-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190248809-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399343-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | SMYD3 4442/4885CASR 998/4885SCN10A 352/4885 |
| US-11873300-B2 | Crystalline forms of CFTR modulators | CFTR, SLC26A4, AQP1 | SMYD3 4671/4885CASR 585/4885SCN10A 248/4885 |
| US-20210047323-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | CFTR, SLC26A4, AQP1 | SMYD3 4671/4885CASR 585/4885SCN10A 248/4885 |
| US-11591350-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | SMYD3 3615/4885CASR 215/4885SCN10A 123/4885 |
| US-11866450-B2 | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators | CFTR, SLC26A4, ABCB11 | SMYD3 3844/4885CASR 361/4885SCN10A 338/4885 |
| US-20190248809-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | CFTR, SLC26A4, ABCB11 | SMYD3 3844/4885CASR 361/4885SCN10A 338/4885 |
| US-20210047345-A1 | PROCESS OF MAKING CFTR MODULATORS | CFTR, SLC26A4, TMEM109 | SMYD3 4442/4885CASR 998/4885SCN10A 352/4885 |
| US-20230303589-A1 | CRYSTALLINE FORMS OF CFTR MODULATORS | CFTR, SLC26A4, ABCC4 | SMYD3 4596/4885CASR 1638/4885SCN10A 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.